3. Soleno Therapeutics (NASDAQ:SLNO)
Upside Potential: 175.1%
Soleno Therapeutics (NASDAQ: SLNO) ranks third in our list of the 10 biotechnology stocks with more than 50% upside potential, and the company has been gaining momentum following the commercial launch of its therapy targeting Prader-Willi Syndrome, a rare genetic disorder affecting appetite regulation and metabolism.
The company’s leading treatment, VYKAT XR (Diazoxide Choline Extended-Release), received FDA approval and entered the market in 2025. The therapy represents one of the first pharmaceutical treatments specifically designed to address the underlying metabolic dysfunction associated with Prader-Willi Syndrome, a condition that affects thousands of patients globally.
Wall Street analysts have taken notice of the company’s early commercial performance. H.C. Wainwright analyst Ram Selvaraju recently raised his price target to $120 per share while maintaining a Buy rating, citing stronger-than-expected sales data. Wells Fargo analyst Derek Archila also reiterated his bullish outlook after reviewing the company’s fourth-quarter earnings results.
Archila highlighted that VYKAT XR sales exceeded expectations, demonstrating encouraging market adoption following its launch. Although new patient starts came in slightly below estimates, company management reaffirmed its target of roughly 250 new patient starts per quarter, excluding seasonal fluctuations.
Given the company’s improving revenue profile and strong cash flow outlook, analysts believe Soleno Therapeutics may still be undervalued relative to its long-term growth potential. For investors seeking commercial-stage biotech stocks with rare disease treatments, Soleno continues to attract growing interest.
Click next to see the following stock...
